Masterclass 2018 Speaker Details

Hardik Madlani

Hardik Madlani

Senior VP

Jefferies Healthcare Investment Banking

Hardik K Madlani is a Senior Vice President in Jefferies’ Healthcare Group and focuses on pharmaceutical M&A transactions in the sector. Mr. Madlani has over 11 years of healthcare investment banking experience. Mr. Madlani joined the Jefferies Healthcare Group in 2009. Prior to joining Jefferies, he worked with the UBS Healthcare team in India from 2006 to 2009. He has closed over 40 healthcare M&A and capital market transactions across a range of geographies including UK, Austria, Belgium, Denmark, Spain, Portugal, Italy, India, Egypt, Israel, and US.

Andrew Wells

Andrew Wells



Andrew’s patent practice is principally in the pharmaceutical and chemical fields. He has extensive experience in securing patent protection for pharmaceuticals and specialises in drafting and prosecuting patent applications covering new chemical entities, salts, polymorphs, formulations (including advanced drug delivery technologies), manufacturing processes, medical uses, and medical devices.

 Andrew draws on both his private practice and in-house experience to provide commercially-focused advice to his clients in relation to all patent matters, including patent portfolio management, enforcing patent rights, challenging third party patent rights, providing infringement and validity opinions, and conducting due diligence evaluations to support licensing and acquisition deals. Andrew also has considerable experience in representing clients in opposition and appeal proceedings at the European Patent Office.


Neil Crabb


Frontier IP Group plc

Neil Crabb is Chief Executive of Frontier IP. He co-founded Sigma Capital Group plc and has considerable experience as an investor and director of a wide range of technology and university spin-out companies. He was previously an investment manager at Duncan Lawrie Ltd. with responsibility for a range of managed portfolios investing in smaller UK companies and unquoted technology companies, prior to which he spent four years with Equitable Life Assurance Soc., latterly as investment analyst managing investments in UK small companies and larger stocks in the electronics sector.

Martin Cadman

Martin Cadman

Due Diligence Manager


Martin joined AstraZeneca in April 2018 as a Due Diligence Director within the Business Development Operations team, based in Cambridge.   BDO is a stand-alone business unit that pursues a range of business development opportunities that have a strategic fit with AZ’s portfolio and commercial capabilities, ranging from alliances and acquisitions in AZ’s main therapy areas, to externalisation activities.  BDO works across the full deal life-cycle, from partner networking, due diligence, negotiations and deal-making, to the subsequent alliance and integration management of partnerships.  Martin’s principal role is to manage due diligence for buy- and sell-side deals undertaken by BDO.

Prior to joining AZ, Martin spent 13 years at GlaxoSmithKline, latterly as a Science & Technology Licensing Director within GSK’s Worldwide Business Development function.  Martin gained broad BD and deal team experience at GSK, and led due diligence for over 20 in-licensing opportunities from pre-clinical to late-clinical development stage, including for the licensing of MOR-103 (MorphoSys, anti-GM-CSF mAb, phase 2).   On the sell-side, Martin led diligences for key divestments including the license of ofatumumab (anti-CD20 mAb, phase 3) to Novartis for MS and autoimmune indications.


Luke Kempton


Gowling WLG

With a PhD in Biochemistry, it’s no surprise that Luke Kempton’s main focus is the Life Sciences, a sector he’s been active in for around 15 years.

He mainly divides his time between patent litigation and transactional work, advising on transactions for both ‘Big Pharma’ and small biotech companies. Typical work includes drafting and negotiating licences, product acquisitions, clinical trial agreements, and manufacturing agreements.

Luke also leads the IP transactional team on a diverse range of other technologies, from hi tech to automotive. Whatever the sector, Luke ensures his clients know what IP they are buying in corporate deals, and drafts and negotiates licences to help them achieve their strategic objectives, either as part of larger deals or standalone transactions.

Bob Clay

Bob Clay

Board Director


A leader in drug development and regulatory science with a track record of achievement in delivery regulatory approvals across a diverse range of therapy areas. A strategic thinker with an understanding of the broad range of public policy and business issues affecting healthcare and drug development. A business leader with experience of building external partnerships and internal change management. A strong leader and motivator who has held senior positions in regulatory affairs with a commitment to the development of colleagues and effective application of resources.

Brian McEwan

Brian McEwan


Cognitial Ltd

Brian is an experienced business leader with an in-depth knowledge of the pharmaceutical marketplace.  During his career he has gained significant experience across all aspects of running a pharmaceutical business, with particular strengths in strategy, communication, finance, business development and compliance. 

He helped create and grow the niche speciality pharma company Amdipharm which was bought by Cinven in 2012, staying in the business to merge Amdipharm and Mercury Pharma into AMCo.

Following his full-time executive career Brian has built a portfolio of non-executive and advisory roles.  He was appointed Chairman of Abbey Pharma Limited (t/a Intrapharm Laboratories Limited) as part of an investment by BGF.  Following a period of sustained growth, Abbey was acquired by German pharmaceutical company Riemser Pharma GmbH in November 2015.

Brian continues to develop his interests in working with entrepreneurial companies.

stephen kidner

Stephen Kidner

Chief Scientific Affairs & Operations officer

Alliance Pharma Ltd

Stephen joined Alliance Pharmaceutical in 2013 and since March 2016 has served as their Chief Scientific and Operations Officer.  He is responsible for product supply and compliance worldwide, including due diligence and integration of newly acquired products.  During this period Alliance has tripled its revenues and significantly extended its global reach through its ‘buy and build model’.  Stephen has a background in the development, manufacture and supply chain management of pharmaceutical and healthcare products over a 25-year international career with Wyeth (now Pfizer) and Mundipharma International.  He is a Chemistry graduate and holds a MSc in Pharmaceutics and an MBA.